Mirum Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MIRM Nasdaq 2830 www.mirumpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva - Oct 26th, 2026 4:50 pm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Oct 21st, 2026 2:01 pm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 15th, 2026 2:01 pm
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases - Oct 13th, 2026 7:41 am
Mirum tees up Livmarli label expansion on Phase III liver disease study success - Oct 12th, 2026 9:48 am
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases - Oct 12th, 2026 9:02 am
Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease - Oct 12th, 2026 8:00 am
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases - Oct 12th, 2026 6:00 am
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases - Oct 11th, 2026 3:00 pm
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study - Oct 2nd, 2026 1:02 pm
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval - Sep 30th, 2026 8:18 am
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Sep 29th, 2026 7:20 am
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data? - Sep 29th, 2026 3:08 am
MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy - Sep 28th, 2026 8:45 am
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Sep 28th, 2026 6:38 am
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus - Sep 28th, 2026 6:00 am
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals - Sep 28th, 2026 4:44 am
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Sep 27th, 2026 3:00 pm
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Sep 25th, 2026 5:00 pm
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill - Sep 25th, 2026 12:43 pm